NCT07459452Not yet recruitingPhase 2
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Study to Evaluate the Efficacy and Safety of JYB1904 Injection Combined With Background Therapy in Patients With Perennial Allergic Rhinitis
Jemincare0 sites135 target enrollmentStarted: April 1, 2026Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 2
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 135
- Primary Endpoint
- Change from Baseline in Reflective Total Nasal Symptom Score (rTNSS) at Week 8 (JYB1904 Q8W vs Placebo) or Week 12 (JYB1904 Q12W vs Placebo)
Study Overview
Brief Summary
This Phase II Trial is Meant to Evaluate the Efficacy, and Safety of JYB1904 Injection in Patients With Perennial Allergic Rhinitis.
Detailed Description
This study is a randomized, double-blind, placebo-controlled Phase II study to evaluate the efficacy and safety of JYB1904 injection compared to placebo in patients with PAR.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Adult participants ≥18 years and ≤65 years of age at the time of signing the informed consent form (ICF).
- •Physician-diagnosed PAR at screening, symptoms of allergic rhinitis present for a minimum of 2 years.
- •Participants must have been on stable treatment with intranasal corticosteroids (INCS), with or without other background medications for at least four consecutive weeks before randomization, and rTNSS≥6 at screening.
- •Within 1 year prior to screening or at screening, participants must have positive indoor allergen SPT and/or positive antigen-specific serum IgE to indoor allergens . Participants must have clinical symptoms associated with perennial allergen positivity (assessed by SPT) or positive serum antigen-specific IgE at study entry .
- •A participant who has a known history of dermatographism or identified during the SPT may participate in this study with a positive serum antigen-specific IgE test.
- •Participants who have concomitant asthma must use permitted regular asthma treatment during the study and have been stable in the 3 months prior to screening.
- •Is willing and able to comply with daily eDiary.
- •Participants must complete the eDiary during the baseline evaluation period (2 weeks prior to randomization) and meet the following criteria: (1) complete the eDiary for at least 4 days per week; and (2) rTNSS score ≥6 at randomization (average of Day-7 to Day-1).
Exclusion Criteria
- •Is currently on AIT subcutaneous immunotherapy or sublingual immunotherapy.
- •Have received treatment with any rescue medication or adjustment to background therapy medications during the baseline evaluation period.
- •Prior intolerance or inadequate response to omalizumab.
- •Contraindications or hypersensitivity to antihistamines or intranasal corticosteroids, or history of anaphylaxis.
- •Have a history of seasonal worsening of AR and if the seasonal worsening is expected during the 2-week baseline evaluation period and the 24-week double-blind induction period.
- •Anticipates significant changes in their daily environmental exposure during the 2-week baseline evaluation period and the 24-week double-blind induction period.
- •Has a history of nasal polyps or nasal polyps present at screening, moderate-to-severe nasal septum deviation, or rhinitis secondary to other causes.
- •Has a known history of recurrent acute or chronic sinusitis.
Arms & Interventions
JYB1904 Q8W
Experimental
JYB1904 will be administered SC.
Intervention: JYB1904 (Biological)
JYB1904 Q12W
Experimental
300mg JYB1904 will be administered as a subcutaneous (SC) injection.
Intervention: JYB1904 (Biological)
Placebo
Placebo Comparator
Placebo will be administered SC.
Intervention: Placebo+JYB1904 (Biological)
Outcomes
Primary Outcomes
Change from Baseline in Reflective Total Nasal Symptom Score (rTNSS) at Week 8 (JYB1904 Q8W vs Placebo) or Week 12 (JYB1904 Q12W vs Placebo)
Time Frame: baseline, Week 8, Week 12
rTNSS was a composite of 4 symptoms (rhinorrhea, nasal congestion, nasal itching and sneezing), each symptom was scored on a scale of 0 = none, 1 = mild, 2 = moderate, 3 = severe. The total score ranged from 0 to 12. The higher the score was, the more severe the symptoms were.
Secondary Outcomes
No secondary outcomes reported
Investigators
Similar Trials
Recruiting
Phase 3
Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.NCT07402213Jemincare240
Recruiting
Phase 2
Safety and Efficacy of J147 in Acute Ischemic StrokeNCT07430917Abrexa Pharmaceuticals, Inc.196
Recruiting
Phase 2
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic PainNCT07285018Eli Lilly and Company150
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic ArthritisNCT07321873Janssen Research & Development, LLC240
Recruiting
Phase 2
LY4268989 in Adults With Moderately to Severely Active Ulcerative ColitisNCT07415044Eli Lilly and Company1,431